Bruker Co. (NASDAQ:BRKR) Receives $84.86 Average Price Target from Analysts

Shares of Bruker Co. (NASDAQ:BRKR - Get Free Report) have earned an average rating of "Hold" from the seven research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $84.86.

BRKR has been the topic of a number of recent research reports. Citigroup upped their target price on shares of Bruker from $80.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. JPMorgan Chase & Co. raised shares of Bruker from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. Stifel Nicolaus boosted their target price on shares of Bruker from $63.00 to $81.00 and gave the stock a "hold" rating in a research note on Wednesday, February 14th. UBS Group lifted their price target on Bruker from $94.00 to $102.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Finally, The Goldman Sachs Group upped their price objective on Bruker from $66.00 to $74.00 and gave the stock a "sell" rating in a research report on Wednesday, April 10th.

Bruker Stock Down 1.0 %

BRKR traded down $0.75 during trading hours on Friday, hitting $75.07. 2,025,757 shares of the company's stock were exchanged, compared to its average volume of 913,097. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95. Bruker has a 12-month low of $53.79 and a 12-month high of $94.86. The firm has a market cap of $10.91 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 1.85 and a beta of 1.22. The firm has a 50 day moving average of $84.74 and a 200 day moving average of $76.18.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. During the same period last year, the business posted $0.64 earnings per share. Bruker's revenue was up 5.3% compared to the same quarter last year. Analysts predict that Bruker will post 2.82 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 17th. Shareholders of record on Monday, June 3rd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Monday, June 3rd. Bruker's dividend payout ratio is presently 7.27%.

Insider Buying and Selling at Bruker

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the company's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now directly owns 23,147 shares of the company's stock, valued at approximately $2,084,618.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 28.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bruker

A number of large investors have recently modified their holdings of the business. Tidal Investments LLC purchased a new position in Bruker in the 1st quarter valued at approximately $218,000. Iron Triangle Partners LP increased its stake in Bruker by 3.7% in the 1st quarter. Iron Triangle Partners LP now owns 466,521 shares of the medical research company's stock valued at $43,825,000 after purchasing an additional 16,521 shares in the last quarter. Janus Henderson Group PLC increased its stake in Bruker by 3.5% in the 1st quarter. Janus Henderson Group PLC now owns 869,205 shares of the medical research company's stock valued at $81,648,000 after purchasing an additional 29,566 shares in the last quarter. Mount Yale Investment Advisors LLC grew its holdings in Bruker by 103.0% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 10,417 shares of the medical research company's stock valued at $979,000 after buying an additional 5,286 shares during the last quarter. Finally, Magnetar Financial LLC grew its holdings in Bruker by 36.6% during the 1st quarter. Magnetar Financial LLC now owns 183,220 shares of the medical research company's stock valued at $17,212,000 after buying an additional 49,057 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.